Loading ...
Sorry, an error occurred while loading the content.
 

Interferon based therapies can reverse fibrosis in HCV infected

Expand Messages
  • claudine intexas
    http://www.veritasmedicine.com/d_home.cfm?type=WU&did=7&cid=72576 Chinweike Ukomadu, M.D., Ph.D. Instructor in Medicine, Harvard Medical School Interferon
    Message 1 of 1 , Apr 27, 2003
      http://www.veritasmedicine.com/d_home.cfm?type=WU&did=7&cid=72576
      Chinweike Ukomadu, M.D., Ph.D.
      Instructor in Medicine, Harvard Medical School

      Interferon based therapies can reverse fibrosis in HCV infected
      patients
      05/31/2002

      Progressive deposition of scar tissue (fibrosis) is the hallmark of
      chronic hepatitis C infection. In its most severe form, the normal
      architecture of the liver is distorted and cirrhosis is present. Over
      the last few years, the mainstay of therapy for chronic HCV infection
      has been the use of interferon in its unmodified or modified
      (pegylated) alone or in combination with ribavirin. A new study
      reported recently in Gastroenterology evaluates the role of the
      multiple interferon-based regimens of the last decade on disease
      progression in treated patients.
      The authors of this study evaluated pre- and post-treatment biopsies
      of over 3,000 patients who had been treated with interferon based
      regimens (10 regimens were evaluated). The analysis of these
      biopsies showed that the degree of inflammation improved in 39%
      (regular interferon alone for 24 weeks) to 73% (optimal weight based
      pegylated interferon and ribavirin). In addition, the rate of
      progression of cirrhosis was reduced in all treatment regimens. The
      most astonishing finding though was that cirrhosis reversal was
      evident in 75 of 143 patients (49%) who had histologic evidence of
      cirrhosis prior to treatment.

      This study supports already existing ideas that cirrhosis may be
      reversed. More importantly, it offers enormous hope to patients who
      brave months of therapy in order to achieve viral suppression. Maybe
      it is no longer too late to treat.

      Reference:

      Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z,
      Ling MH, Albrecht J. Impact of pegylated interferon alfa-2b and
      ribavirin on liver fibrosis in patients with chronic hepatitis C.
      Gastroenterology. 2002 May;122(5):1303-13


      __________________________________
      Do you Yahoo!?
      The New Yahoo! Search - Faster. Easier. Bingo.
      http://search.yahoo.com
    Your message has been successfully submitted and would be delivered to recipients shortly.